Diakonie-Krankenhaus, Schwäbisch Hall, Germany.
Oncology. 2010;79(3-4):247-54. doi: 10.1159/000322866. Epub 2011 Mar 3.
This multicenter, retrospective survey evaluated the efficacy and safety of bortezomib retreatment in patients with relapsed multiple myeloma who had responded to initial bortezomib treatment.
Clinical records of 94 patients receiving bortezomib retreatment in Germany and Switzerland were reviewed.
Sixty patients were included according to prespecified criteria. Patients had received a mean 3.7 ± 2.3 therapies prior to initial bortezomib. Overall response rate to bortezomib retreatment was 63.3%; 8 (13.3%), 3 (5.0%) and 27 (45.0%) patients achieved complete response (CR), near-CR and partial response, respectively. Response to retreatment was associated with response to initial treatment (75.0% of patients with CR to initial treatment responded to retreatment) and treatment-free interval (TFI) after initial treatment (76.9 vs. 38.1% overall response rate for patients with TFI >6 vs. ≤ 6 months). After retreatment, median time to progression was 9.3 months. Median TFI was 5.7 months; 31.7, 25.0 and 15.0% of patients experienced a TFI longer than 6, 9 and 12 months, respectively. Reported adverse drug reactions were consistent with the known safety profile of bortezomib and most resolved completely.
These results demonstrate that relapsed multiple myeloma patients who respond to initial bortezomib treatment have a sustained susceptibility to bortezomib and do not experience uncommon toxicity to retreatment.
这项多中心、回顾性研究评估了硼替佐米复治对初始硼替佐米治疗有反应的复发性多发性骨髓瘤患者的疗效和安全性。
对在德国和瑞士接受硼替佐米复治的 94 例患者的临床记录进行了回顾。
根据预设标准纳入 60 例患者。患者在接受初始硼替佐米治疗前平均接受了 3.7±2.3 次治疗。硼替佐米复治的总缓解率为 63.3%；8（13.3%）例、3（5.0%）例和 27（45.0%）例患者分别达到完全缓解（CR）、接近完全缓解和部分缓解。复治的缓解与初始治疗的缓解相关（初始治疗 CR 的患者中有 75.0%对复治有反应）和初始治疗后无治疗间隔（TFI）相关（TFI>6 个月与≤6 个月的患者总体缓解率分别为 76.9%和 38.1%）。复治后，中位无进展生存期为 9.3 个月。中位 TFI 为 5.7 个月；31.7%、25.0%和 15.0%的患者 TFI 分别超过 6、9 和 12 个月。报告的药物不良反应与硼替佐米已知的安全性特征一致，大多数完全缓解。
这些结果表明，对初始硼替佐米治疗有反应的复发性多发性骨髓瘤患者对硼替佐米仍有持续敏感性，且复治不会产生不常见的毒性。
